Wednesday, Johnson & Johnson (NYSE:JNJ) revealed results from a head-to-head study of Erleada (apalutamide) compared to ...

While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi ...

Johnson & Johnson today released results of a landmark real-world head-to-head study showing that Erleada (apalutamide) ...

Based on real-world data, Johnson & Johnson (NYSE:JNJ) announced Wednesday its prostate cancer therapy Erleada (apalutamide) ...

(RTTNews) - Johnson & Johnson (JNJ), Wednesday announced results from a head-to-head study, demonstrating statistically significant overall survival benefit in patients on Erleada at 24 months ...

Erleada is a successor to J&J’s Zytiga (abiraterone), which has gone off patent in the US and succumbing to generic competition – sales of the blockbuster were down nearly 60% in Q2 in the US ...

Erleada plus ADT, compared with placebo plus ADT, achieved a 34% risk reduction in median time to second progression-free survival (PFS2), defined as time from randomisation to either disease ...

Johnson & Johnson JNJ filed for voluntary bankruptcy for the third time in an attempt to bring an end to thousands of ...

Johnson & Johnson's stock has seen modest gains in recent months. Read why I downgrade JNJ stock from buy to hold.

ESMO Congress, an expert explained how Nubeqa may reduce fatigue-related side effects in metastatic hormone-sensitive ...

Johnson & Johnson’s (NYSE:JNJ) is the producer of some top-selling drugs which include Stelaera, Darzalex, Imbruvica, Tremfya, Erleada, Uptravi, Invega, Symtuza, and Opsumit. In the second ...

Johnson & Johnson’s (NYSE:JNJ) top-selling drugs include Stelaera, Darzalex, Imbruvica, Tremfya, Erleada, Uptravi, Invega, Symtuza, and Opsumit. In the second quarter of 2024, the company ...